T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Clinical trials for T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take aim at stubborn blood cancers
Disease control Recruiting nowThis study tests a new type of immunotherapy called CAR-T cells that are designed to recognize and attack cancer cells carrying a protein called CD7. It includes people with several blood cancers, such as T-cell acute lymphoblastic leukemia and acute myeloid leukemia. The goal is…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New universal CAR t therapy targets tough blood cancers
Disease control Recruiting nowThis early-stage trial tests a new type of immune cell therapy (called universal CAR T cells) for people with certain blood cancers, including T-cell leukemia and lymphoma. The therapy targets a protein called CD7 found on cancer cells. The study will check if the treatment is sa…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Double-Barreled immune attack aims to wipe out T-ALL
Disease control Recruiting nowThis early-phase trial tests a two-part immune therapy for people with T-cell acute lymphoblastic leukemia (T-ALL). First, patients receive specially engineered T cells (CAR-T) that target multiple markers on leukemia cells. Then, they get a booster with cytotoxic T cells and a d…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug aimed at wiping out hidden leukemia cells after chemo
Disease control Recruiting nowThis study tests whether daratumumab can eliminate tiny amounts of leukemia that remain after chemotherapy in people with T-cell acute lymphoblastic leukemia (T-ALL). About 20 adults whose cancer has come back or not fully cleared will receive the drug. The goal is to see if it c…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Eastern Cooperative Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail aims to beat back tough blood cancers in young patients
Disease control Recruiting nowThis early-phase study tests a combination of four drugs (venetoclax, dexamethasone, bortezomib, and daratumumab) for teens and young adults aged 12 to 30 whose T-cell acute lymphoblastic leukemia or lymphoma has returned or not responded to prior treatment. The main goal is to c…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Supercharged immune cells take on tough blood cancers
Disease control Recruiting nowThis study tests a new treatment for people with blood cancers like leukemia, lymphoma, and multiple myeloma that have returned or not responded to treatment. Participants receive chemotherapy followed by specially engineered natural killer (NK) cells from donated cord blood. The…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Engineered donor cells take aim at tough T-Cell cancers
Disease control Recruiting nowThis early-phase study tests a new treatment for people with T-cell leukemia or lymphoma that has come back. The treatment uses specially trained immune cells from a healthy donor, designed to recognize and attack cancer cells carrying a marker called CD7. The goal is to see if t…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Donor immune cells take on tough T-Cell cancers in new trial
Disease control Recruiting nowThis phase 2 trial tests a one-time infusion of WU-CART-007, a CAR-T cell therapy made from healthy donor cells, in 125 people with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma that has come back or not responded to treatment. The goal is to see if it can wipe ou…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Wugen, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New combo therapy aims to wipe out leukemia in adults who Can't take standard treatment
Disease control Recruiting nowThis study tests a combination of chemotherapy drugs (DA-EPOCH) plus an enzyme called asparaginase (Rylaze) in adults newly diagnosed with a fast-growing blood cancer (Philadelphia chromosome-negative ALL). The goal is to see if this mix can kill more cancer cells and achieve dee…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New hope for kids with tough leukemia: targeted drugs added to chemo
Disease control Recruiting nowThis study tests whether adding dasatinib or venetoclax to standard chemotherapy can help more children with T-cell acute lymphoblastic leukemia or lymphoma achieve a deep remission. About 100 children and young adults aged 1 to 18 will receive one of these targeted drugs alongsi…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New immunotherapy combo aims to stop relapse in young blood cancer patients
Disease control Recruiting nowThis early-phase trial tests whether adding daratumumab (an immunotherapy drug) after a stem cell transplant can safely help control high-risk T-cell acute lymphoblastic leukemia or lymphoma in children, teens, and young adults up to age 39. About 30 participants will receive the…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: New York Medical College • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Experimental cocktail aims to tackle tough blood cancers
Disease control Recruiting nowThis study tests a new drug called LP-118 combined with three existing cancer medicines (ponatinib, vincristine, and dexamethasone) in adults with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back or not responded to treatment. The goal is to…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Promising combo aims to boost remission in rare blood cancer
Disease control Recruiting nowThis study tests whether combining venetoclax with azacitidine can help people with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) achieve remission. About 28 participants aged 15 and older will receive the drug combination for up to two 21-day cycles. The main goal …
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New enzyme combo aims to boost leukemia treatment in High-Risk adults
Disease control Recruiting nowThis study tests whether a new form of the drug asparaginase (made from a different bacterium) can be safely combined with standard chemotherapy for high-risk adults aged 18–54 with newly diagnosed acute lymphoblastic leukemia or lymphoblastic lymphoma. The treatment aims to kill…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New stem cell transplant method shows promise for kids with tough blood cancers
Disease control Recruiting nowThis study tests a new way to do stem cell transplants for children with blood cancers like leukemia. It uses a half-matched family donor and removes certain immune cells from the donated cells to lower risks. The goal is to see if this method is safe and helps the child's body a…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Promising drug cocktail targets tough blood cancers in kids
Disease control Recruiting nowThis study tests whether a combination of three drugs—calaspargase pegol-mknl, decitabine, and venetoclax—can help control relapsed or treatment-resistant T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LLy) in patients aged 1 month to 21 years. T…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Engineered cells take on tough blood cancer in first human trial
Disease control Recruiting nowThis early-phase study tests a new treatment called OC-1, which uses a patient's own immune cells (T cells) that have been modified in a lab to recognize and attack a specific marker (CD1a) on cancer cells. The trial aims to see if this therapy is safe and can help shrink or elim…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: OneChain Immunotherapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Experimental CAR T-Cell therapy targets tough leukemias
Disease control Recruiting nowThis early-phase trial is testing an experimental treatment called CART84 for people with acute myeloid leukemia (AML) or T-cell acute lymphoblastic leukemia (T-ALL) that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified in a lab…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Gyala Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for tough leukemia: capivasertib combo enters human trials
Disease control Recruiting nowThis study tests whether adding the experimental drug capivasertib to a standard treatment (venetoclax plus low-intensity chemotherapy) is safe and effective for adults with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma that has come back or not responded to prior …
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New hope for tough leukemia cases: drug combo trial opens for kids and young adults
Disease control Recruiting nowThis study is for children, teens, and young adults (ages 1 to 39) with acute leukemia that has come back or not gotten better with standard treatments. Researchers are testing whether combining two drugs—venetoclax and Vyxeos—is safe and tolerable. The goal is to find the best d…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Could new immune drugs replace transplants for leukemia patients?
Disease control Recruiting nowThis study tests whether adding newer antibody-based drugs to standard chemotherapy can improve survival and reduce the need for stem cell transplants in adults with acute lymphoblastic leukemia (ALL). About 1,200 patients aged 18–65 with newly diagnosed ALL will be assigned to o…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2, PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Cord blood cells engineered to fight Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests a new treatment using immune cells (NK cells) from donated cord blood that are engineered to target a protein called CD5 found on certain cancer cells. The treatment is given after chemotherapy to prepare the body, and the goal is to see if it is safe and effecti…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Engineered immune cells take on childhood blood cancers in early trial
Disease control Recruiting nowThis early-phase trial tests a new type of immune therapy called CD70-CAR T cells in children and young adults up to age 21 with blood cancers that have come back or not responded to treatment. The therapy involves taking the patient's own immune cells, engineering them to recogn…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New combo therapy aims to crush T-Cell blood cancers
Disease control Recruiting nowThis phase II trial is testing a combination of chemotherapy drugs plus nelarabine in 160 people with previously untreated T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. The goal is to see if this stronger cocktail can improve remission rates and help people live …
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Engineered immune cells take on tough T-Cell cancers
Disease control Recruiting nowThis early-stage trial tests whether a new type of CAR T-cell therapy is safe for children and adults with T-cell leukemia or lymphoma that has come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified in a lab to target a protein …
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: University College, London • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Engineered immune cells take on tough T-Cell cancers
Disease control Recruiting nowThis study tests a new treatment called CD7 CAR T-cell therapy for people with T-cell cancers that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells or cells from a donor, which are modified to find and attack cancer cells. The …
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Engineered immune cells take on tough leukemia in kids
Disease control Recruiting nowThis early-stage trial is testing a type of immunotherapy called CAR T cells in children, adolescents, and young adults with acute lymphoblastic leukemia that has come back or not responded to standard treatments. The therapy involves taking the patient's own immune cells or dono…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Instituto de Investigación Hospital Universitario La Paz • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Genetically modified t cells take aim at Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-phase trial is testing a new type of immunotherapy for people with T-cell leukemia or lymphoma that has returned. The treatment involves taking a patient's own immune cells (or cells from a past stem cell donor), adding a special receptor that targets a protein called …
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 26, 2026 13:32 UTC
-
New screening trial aims to match kids with relapsed leukemia to targeted therapies
Knowledge-focused Recruiting nowThis study screens children and young adults up to age 22 whose leukemia has returned or is hard to treat. By testing their blood and bone marrow, doctors can identify specific genetic markers to match them with the most promising experimental treatments. The goal is to build a r…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: PedAL BCU, LLC • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC